4Hjiyiannakis P, Mundy J, Harmer C. Thyroglobulin antibodies in dif- ferentiated thyroid cancer[ J]. Clin Oncol, 1999,11 (4) :240-244.
5Cooper D S, Doherty G M, Haugen B R, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer [J]. Thyroid,2006,16(2) :109-142.
3Mazzaferri EL, Robbins R J, Spencer CA, et al. A consensus report of the role of serum thyroglobublin as a monitoring method for low-risk patientswithpapillarythyroidcarcinoma [J]. JClinEndocrinol Meta, 2003, 88(4): 1433-1441.
4Pacini F, Fugazzola L, Lippi F, et al. Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer [J]. J Clin Endocrinol Metab, 1992, 74(6): 1401-1404.
5Spencer CA, Wang C, Fatemi S, et al. Serum thyroglobulin autoanti bodies: Prevalence, influence on serum thyroglobulin measurement and prognostic significance in patients with differentiated thyroid carcinoma[J]. J Clin Endocrinol Metab, 1998, 83(4): 1121
6Massart C, Maugendre D. Importance of the detection method for thyroglobulin antibodies for the validity of thyroglobulin measurements in sera from patients with Graves' disease[J]. Clin Chem, 2002,48(1): 102-107.
7Girelli ME, De Vido D. Serum thyroglobulin measurements in differentiated thyroid cancer[J]. Biomed Pharmacother, 2000, 54(6): 330-333.
8Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyroglobulin assays[J]. Clin Chem, 1996, 42(1): 164-173.
9Hjiyiannakis P, Mundy J, Harmer C. Thyroglobulin antibodies in differentiated thyroid cancer[J]. Clin Oncol, 1999, 11(4): 240-244.
10Cailleux A F, Baudin E, Travagli J P, et al. Is diagnostic indine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?[J]. Clin Endoerinol Metab, 2000, 85(1) :175-178.
3Rego-Iraeta A, Perez-Mendez LF, Mantinan B, et al. Time trends for thyroid cancer in northwestern Spain: true rise in the incidence of micro and larger forms of papi\lary thyroid carcinoma[J]. Thyroid, 2009, 19(4): 333-40.
4Yuksel 0, Kurukahvecioglu 0, Ege B, et al. The relation between pure papi\lary and follicular variant in papi\lary thyroid carcinoma[J]. Endocr Regul, 2008, 42(1): 29-33.
5Pacini F, Sabra MM, Tuttle RM. Clinical relevance of thyroglobulin doubling time in the management of patients with differentiated thy?roid cancer[J]. Thyroid, 2011, 21(7): 691-692.
6Albrecht AM, Paulson CP, Kovach FE. Clinical inquiries. What's the best way to monitor low-risk patients with a history of differentiat?ed thyroid cancer?[J]. J Fam Pract, 2009, 58: E4.
7Park YJ, Kwak SH, Kim DC, et al. Diagnostic value of galectin-3, HBME-l, cytokeratin 19, high molecular weight cytokeratin, cyelin Dl and p27(kipl) in the differential diagnosis of thyroid nodules[J]. J Korean Med Sci, 2007, 22: 621-628.
8Sapio MR, Guerra A, Posca D, et al. Combined analysis of galee?tin-3 and BRAFV600E improves the accuracy of fine-needle aspira?tion biopsy with cytological findings suspicious for papi\lary thy?roid carcinoma[J]. Endocr Relat Cancer, 2007, 14: 1089-1097.
9Liu YY, Morreau H, Kievit J, et al. Combined immunostaining with galectin-3, fibronectin-l, CITED-I, Hector Battifora mesotheli?al-I, cytokerann-Is, peroxisome proliferator-activated recep?tor-{garnma}, and sodium/iodide symporter antibodies for the differ?ential diagnosis of non-medullary thyroid carcinoma[J]. Eur J En?docrinol,2008, 158: 375-384.
10Spencer C, Petrovic I, Fatemi S. Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer[J]. J Clin Endocrinol Metab, 20Il, 96(5): 1283-1291.
